Earnings summaries and quarterly performance for Intellia Therapeutics.
Executive leadership at Intellia Therapeutics.
John Leonard
Detailed
President and Chief Executive Officer
CEO
BS
Birgit Schultes
Detailed
Executive Vice President, Chief Scientific Officer
DL
David Lebwohl
Detailed
Executive Vice President, Chief Medical Officer
ED
Edward Dulac
Detailed
Executive Vice President, Chief Financial Officer and Treasurer
EC
Eliana Clark
Detailed
Executive Vice President, Chief Technology Officer
JB
James Basta
Detailed
Executive Vice President, General Counsel and Corporate Secretary
Board of directors at Intellia Therapeutics.
Research analysts who have asked questions during Intellia Therapeutics earnings calls.
LI
Luca Issi
RBC Capital Markets
4 questions for NTLA
Also covers: ADVM, ALLO, ALNY +12 more
YZ
Yanan Zhu
Wells Fargo Securities
4 questions for NTLA
Also covers: ADAP, AFMD, ARCT +13 more
BC
Brian Cheng
JPMorgan Chase & Co.
3 questions for NTLA
Also covers: ALLO, CHRS, EDIT +6 more
DL
David Lebowitz
Citigroup Inc.
3 questions for NTLA
Also covers: ALNY, ARWR, ASND +11 more
Jay Olson
Oppenheimer & Co. Inc.
3 questions for NTLA
Also covers: ACAD, AMGN, BIIB +22 more
MR
Maurice Raycroft
Jefferies Financial Group
3 questions for NTLA
Also covers: ABEO, AFMD, ALNY +14 more
Rick Bienkowski
Cantor Fitzgerald
3 questions for NTLA
Also covers: BEAM, LEGN
WP
William Pickering
Sanford C. Bernstein & Co.
3 questions for NTLA
Also covers: ALLO, ARWR, REGN +1 more
Alec Stranahan
Bank of America
2 questions for NTLA
Also covers: AGIO, ALEC, BTAI +11 more
Andy Chen
Wolfe Research, LLC
2 questions for NTLA
Also covers: ARGX, CRNX, IMVT +7 more
HW
Huidong Wang
Barclays
2 questions for NTLA
Also covers: ALNY, BCRX, BEAM +15 more
Joseph Thome
TD Cowen
2 questions for NTLA
Also covers: ALKS, AMLX, ARDX +12 more
KB
Konstantinos Biliouris
BMO Capital Markets
2 questions for NTLA
Also covers: ALNY, BEAM, BMRN +3 more
MF
Mani Foroohar
Leerink Partners
2 questions for NTLA
Also covers: ADVM, ALNY, ARWR +9 more
Mitchell Kapoor
H.C. Wainwright & Co.
2 questions for NTLA
Also covers: CTMX, HALO, INM +7 more
MM
Myles Minter
William Blair & Company
2 questions for NTLA
Also covers: ALEC, ARCT, ARGX +11 more
Salveen Richter
Goldman Sachs
2 questions for NTLA
Also covers: ACAD, AGIO, ALLO +20 more
ST
Silvan Tuerkcan
Citizens JMP
2 questions for NTLA
Also covers: CLLS, EXEL, MGNX +2 more
TL
Troy Langford
TD Cowen
2 questions for NTLA
Also covers: ALKS, AXSM, JAZZ
Brandon Frith
Wolfe Research, LLC
1 question for NTLA
Also covers: INSM, ROIV
Cheng Li
Oppenheimer & Co. Inc.
1 question for NTLA
Also covers: EDIT, EXEL, INO +3 more
DG
Dae Gon Ha
Stifel
1 question for NTLA
Also covers: ABEO, BEAM, CRBP +10 more
Farzin Haque
Jefferies
1 question for NTLA
Also covers: ABEO, ARWR, AUPH +3 more
Gena Wang
Barclays
1 question for NTLA
Also covers: ALNY, BCRX, BLUE +12 more
Hang Hu
Barclays
1 question for NTLA
Also covers: VIR
HT
Hannah Tran
Wolfe Research
1 question for NTLA
Jonathan Miller
Evercore ISI
1 question for NTLA
Also covers: APLS, ARVN, ATRA +8 more
JL
Joon Lee
Truist Securities
1 question for NTLA
Also covers: ADVM, AXSM, CNM +14 more
Kostas Biliouris
BMO Capital Markets
1 question for NTLA
Also covers: ALNY, BMRN, LEGN +2 more
Liisa Bayko
Evercore ISI
1 question for NTLA
Also covers: ALT, BCRX, INSM +7 more
LN
Lili Nsongo
iA Capital Markets
1 question for NTLA
Also covers: ARCT, VYGR
LM
Lut Ming Cheng
JPMorgan Chase & Co.
1 question for NTLA
Also covers: ALLO, CHRS, EDIT +3 more
Mark Aleynick
Goldman Sachs
1 question for NTLA
Also covers: ALLO, FOLD
Matthew Guggenbiller
Bank of America
1 question for NTLA
Also covers: AGIO
MH
Matthew Harrison
Bank of America
1 question for NTLA
Also covers: RVMD
Mehdi Goudarzi
Truist Securities
1 question for NTLA
Also covers: ARGX, EDIT, RARE +1 more
Ry Forseth
Guggenheim Securities
1 question for NTLA
Also covers: KRYS, SLNO, SRPT +1 more
Terence Flynn
Morgan Stanley
1 question for NTLA
Also covers: ABBV, AMGN, ARVN +17 more
WI
Whitney Ijem
Canaccord Genuity Inc.
1 question for NTLA
Also covers: ARCT, BOLD, GUTS +4 more
WS
William Sanger
Leerink Partners
1 question for NTLA
Yuriy Slutskyy
BMO Capital Markets
1 question for NTLA
Recent press releases and 8-K filings for NTLA.
Intellia Therapeutics Updates on Clinical Pipeline and Financial Outlook
NTLA
Product Launch
Guidance Update
New Projects/Investments
- Intellia Therapeutics' Lombozi program for hereditary angioedema (HAE) has completed enrollment for its Phase 3 HAELO trial, with top-line data anticipated by mid-2026, a Biologics License Application (BLA) submission in H2 2026, and a commercial launch expected in H1 2027.
- The Nexi program for transthyretin amyloidosis (TTR) is currently under a clinical hold by the FDA, which was triggered by a patient death due to septicemia from a perforated duodenal ulcer, not liver failure. Intellia is actively engaged with the FDA to resolve the hold.
- The company reports a strong financial position, with capital to fund operations into mid-2027.
6 days ago
Intellia Therapeutics Provides Clinical and Financial Updates at JPMorgan Healthcare Conference
NTLA
Product Launch
New Projects/Investments
Guidance Update
- Intellia Therapeutics announced the completion of enrollment for its Lombozi (HAE) Phase 3 Halo trial, with top-line data expected by mid-2026, a Biologics License Application (BLA) submission in H2 2026, and a commercial launch targeted for H1 2027.
- The company's Nexi (TTR amyloidosis) Phase 3 trials (Magnitude and Magnitude-2) are currently on clinical hold, with Intellia actively engaged with the FDA for resolution.
- Intellia clarified that the patient death which led to the Nexi clinical hold was attributed to septicemia from a perforated duodenal ulcer, not liver failure.
- Intellia maintains a strong capital position, providing funding for operations into mid-2027.
6 days ago
Intellia Therapeutics Provides Update on Late-Stage Clinical Programs and Financial Outlook
NTLA
Product Launch
New Projects/Investments
Guidance Update
- Intellia Therapeutics, a leader in CRISPR medicine, is advancing two late-stage clinical programs: Lombozi for hereditary angioedema (HAE) and Nexi for transthyretin amyloidosis (TTR).
- For Lombozi, the Phase 3 Halo trial enrollment is complete, with top-line data anticipated by mid-2026, BLA submission in H2 2026, and a commercial launch targeted for H1 2027.
- The Nexi Phase 3 programs for TTR amyloidosis are currently under clinical hold, with resolving this hold being a top priority for 2026. The hold was triggered by a patient who succumbed to septicemia due to a perforated duodenal ulcer, not liver failure.
- The company maintains a strong capital position, providing funding for operations into mid-2027.
6 days ago
Intellia Therapeutics provides update on nex-z clinical holds and lonvo-z development
NTLA
New Projects/Investments
Guidance Update
Product Launch
- Intellia Therapeutics' nexiguran ziclumeran (nex-z) MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for transthyretin (ATTR) amyloidosis are on clinical hold following a Grade 4 liver transaminase elevation in a patient who subsequently passed away on November 5, 2025, due to septic shock secondary to a perforated duodenal ulcer.
- The company is working to resolve the clinical holds and plans to provide an update after finalizing a path forward with regulators for nex-z.
- Intellia expects to present topline Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) by mid-2026, with a Biologics License Application (BLA) submission planned for the second half of 2026 and a U.S. commercial launch in the first half of 2027.
- Intellia anticipates its existing capital will fund operations into mid-2027.
Jan 9, 2026, 1:07 PM
Intellia Therapeutics Presents Positive Lonvoguran Phase 1/2 Data
NTLA
New Projects/Investments
- Intellia Therapeutics announced positive pooled Phase 1/2 clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based gene editing therapy for hereditary angioedema (HAE), on November 8, 2025.
- Among 32 patients who received a 50 mg dose of lonvo-z, 31 (97%) were attack-free and long-term prophylaxis (LTP)-free as of the August 29, 2025 data cutoff.
- 75% of patients (24 out of 32) remained attack-free and LTP-free for at least seven months (up to 32 months), with a mean reduction in plasma kallikrein of 89% at month 24.
- The therapy demonstrated a well-tolerated safety profile with up to three years of follow-up and no new long-term risks identified.
- The company expects to report topline data from the ongoing Phase 3 HAELO clinical trial for lonvo-z by mid-2026, with enrollment completed in September 2025.
Nov 10, 2025, 10:24 PM
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran
NTLA
- Intellia Therapeutics announced positive longer-term follow-up data from its Phase 1 clinical trial of nexiguran ziclumeran (nex-z) in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy.
- A single dose of nex-z led to a consistently rapid, deep, and durable reduction in serum TTR, with a mean reduction of 87% among patients reaching 36 months of follow-up.
- Patients demonstrated disease stability or improvement at 24 months in multiple cardiomyopathy markers, including NT-proBNP (70% of patients), hs-Troponin T (85% of patients), and NYHA classification (81% of patients).
- A post-hoc mortality assessment showed nex-z patients had an all-cause mortality rate of 3.9 per 100 patient-years, significantly lower than the 12.7 per 100 patient-years in a matched cohort (HR 0.27, p=0.009).
- The company is currently working to address an ongoing clinical hold placed by the FDA on its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z.
Nov 10, 2025, 8:17 PM
Intellia Therapeutics Presents Positive Phase 1/2 Data for Lonvo-z in HAE
NTLA
New Projects/Investments
- Intellia Therapeutics presented positive pooled Phase 1/2 clinical data for its investigational gene editing therapy, lonvo-z, for hereditary angioedema (HAE) on November 8, 2025.
- Among 32 patients who received a 50 mg dose of lonvo-z, 31 (97%) were attack-free and long-term prophylaxis-free, with 24 (75%) remaining so for at least seven months (up to 32 months).
- The therapy demonstrated deep, stable, and durable reductions in plasma kallikrein (mean 89% at month 24) and a well-tolerated safety profile with up to three years of follow-up.
- Lonvo-z is being evaluated as a potential first one-time treatment for HAE, with topline data from the Phase 3 HAELO clinical trial expected by mid-2026.
Nov 8, 2025, 10:13 PM
Intellia Suspends Gene Therapy Trials Following Patient Death
NTLA
New Projects/Investments
- Intellia Therapeutics has temporarily halted dosing and screening for its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of the CRISPR-based gene therapy Nex-z.
- This action follows the death of a patient in his early 80s with transthyretin amyloidosis, who experienced severe liver-related side effects including grade 4 liver transaminase elevations and increased total bilirubin.
- The FDA has placed a clinical hold on both trials, and Intellia is collaborating with regulatory authorities and experts to evaluate the liver-related events and develop a risk mitigation plan.
- Intellia's shares dropped significantly following the news, reflecting investor concerns over the safety of the gene-editing treatment.
Nov 7, 2025, 5:23 PM
Intellia Therapeutics Reports Q3 Loss Amid Clinical Hold on Lead Candidate
NTLA
Earnings
New Projects/Investments
Guidance Update
- Intellia Therapeutics reported a narrower-than-expected Q3 2025 loss of 92 cents per share and revenue growth to $13.78 million, primarily driven by collaboration revenues from Regeneron.
- The company faced a significant setback as its lead cardiovascular candidate, nexiguran ziclumeran (nex-z), was placed on an FDA clinical hold following a patient death due to severe liver-related adverse events in the Phase III MAGNITUDE trial.
- Despite the regulatory hold on nex-z, Intellia completed patient enrollment for its pivotal Phase III HAELO trial of lonvoguran ziclumeran (lonvo-z), with results expected by mid-2026 and a projected U.S. launch in 2027.
- Intellia's financial position remains solid, with cash reserves expected to sustain operations into mid-2027, and analysts maintain a bullish outlook with a median 12-month price target of $24.50.
- Research and development expenses decreased by 23% year-over-year in Q3 2025, mainly due to lower employee-related expenses and stock-based compensation.
Nov 7, 2025, 12:04 PM
Intellia Therapeutics Announces Q3 2025 Financial Results and Clinical Program Updates
NTLA
Earnings
Guidance Update
New Projects/Investments
- Intellia Therapeutics reported a net loss of $101.3 million for the third quarter of 2025 and ended the quarter with $669.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into mid-2027.
- The FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z following a patient death and reported Grade 4 liver transaminase elevations in less than one percent of patients in MAGNITUDE.
- Enrollment was completed in the Phase 3 HAELO clinical trial of lonvo-z for HAE, with topline data anticipated by mid-2026 and a potential U.S. commercial launch in 1H27.
- During Q3 2025, the company raised $114.5 million in net equity proceeds from its "At the Market" (ATM) program.
Nov 6, 2025, 9:06 PM
Quarterly earnings call transcripts for Intellia Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more